Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

BCMA-targeted immunotherapy for multiple myeloma
Bo Yu, Tianbo Jiang, Delong Liu
Journal of Hematology & Oncology (2020) Vol. 13, Iss. 1
Open Access | Times Cited: 160

Showing 26-50 of 160 citing articles:

T-cell-engaging antibodies for the treatment of solid tumors: challenges and opportunities
Patrick A. Baeuerle, Holger Wesche
Current Opinion in Oncology (2022) Vol. 34, Iss. 5, pp. 552-558
Open Access | Times Cited: 35
BCMA loss in the epoch of novel immunotherapy for multiple myeloma: from biology to clinical practice
Xiang Zhou, Leo Rasche, K. Martin Kortüm, et al.
Haematologica (2022) Vol. 108, Iss. 4, pp. 958-968
Open Access | Times Cited: 32
Armored BCMA CAR T Cells Eliminate Multiple Myeloma and Are Resistant to the Suppressive Effects of TGF-β
Leah Alabanza, Ying Xiong, Bang K. Vu, et al.
Frontiers in Immunology (2022) Vol. 13
Open Access | Times Cited: 31
Effects of teclistamab and talquetamab on soluble BCMA levels in patients with relapsed/refractory multiple myeloma
Suzette Girgis, Shun Xin Wang Lin, Kodandaram Pillarisetti, et al.
Blood Advances (2022) Vol. 7, Iss. 4, pp. 644-648
Open Access | Times Cited: 29
Anti-BCMA novel therapies for multiple myeloma
Vincenzo Sammartano, Marta Franceschini, Sara Fredducci, et al.
Cancer Drug Resistance (2023) Vol. 6, Iss. 1, pp. 169-181
Open Access | Times Cited: 18
Management of Relapsed–Refractory Multiple Myeloma in the Era of Advanced Therapies: Evidence-Based Recommendations for Routine Clinical Practice
Danai Dima, Fauzia Ullah, Sandra Mazzoni, et al.
Cancers (2023) Vol. 15, Iss. 7, pp. 2160-2160
Open Access | Times Cited: 18
Renal AL Amyloidosis: Updates on Diagnosis, Staging, and Management
Areez Shafqat, Hassan Elmaleh, Ali Mushtaq, et al.
Journal of Clinical Medicine (2024) Vol. 13, Iss. 6, pp. 1744-1744
Open Access | Times Cited: 6
The promising role of antibody drug conjugate in cancer therapy: Combining targeting ability with cytotoxicity effectively
Wen‐Qian Li, Hanfei Guo, Lingyu Li, et al.
Cancer Medicine (2021) Vol. 10, Iss. 14, pp. 4677-4696
Open Access | Times Cited: 39
Promising Antigens for the New Frontier of Targeted Immunotherapy in Multiple Myeloma
Shih‐Feng Cho, Lijie Xing, Kenneth C. Anderson, et al.
Cancers (2021) Vol. 13, Iss. 23, pp. 6136-6136
Open Access | Times Cited: 33
The Leading Role of the Immune Microenvironment in Multiple Myeloma: A New Target with a Great Prognostic and Clinical Value
Vanessa Desantis, Francesco Savino, Antonietta Scaringella, et al.
Journal of Clinical Medicine (2022) Vol. 11, Iss. 9, pp. 2513-2513
Open Access | Times Cited: 26
Trends in the Development of Antibody-Drug Conjugates for Cancer Therapy
Chi Hun Song, Minchan Jeong, H. In, et al.
Antibodies (2023) Vol. 12, Iss. 4, pp. 72-72
Open Access | Times Cited: 14
Natural killer cell engagers for cancer immunotherapy
Shahryar Khoshtinat Nikkhoi, Geng Li, Arash Hatefi
Frontiers in Oncology (2025) Vol. 14
Open Access
Comprehensive biomarker profiles in hematological malignancies: improving diagnosis, prognosis, and treatment
Ali Golestan, Mohammadrasul Zareinejad, Amin Ramezani
Biomarkers in Medicine (2025), pp. 1-16
Closed Access
A synthetic heavy chain variable domain antibody library (VHL) provides highly functional antibodies with favorable developability
Guiying Pang, Ruixue Wang, Hongxu Yang, et al.
Protein Science (2025) Vol. 34, Iss. 4
Closed Access
Targeting B Cells for the Treatment of Idiopathic Inflammatory Myopathy
Tao Liu, Bo Chen, Geng Yin, et al.
Clinical Reviews in Allergy & Immunology (2025) Vol. 68, Iss. 1
Open Access
Advances in Gene Therapy with Oncolytic Viruses and CAR-T Cells and Therapy-Related Groups
Yasunari Matsuzaka, Ryu Yashiro
Current Issues in Molecular Biology (2025) Vol. 47, Iss. 4, pp. 268-268
Open Access
The molecular landscape of AL amyloidosis
Tal Zvida‐Bloch, Eli Muchtar, Angela Dispenzieri, et al.
British Journal of Haematology (2025)
Open Access
Harnessing the Immune System Against Multiple Myeloma: Challenges and Opportunities
Leona Yamamoto, Nicola Amodio, Annamaria Gullà, et al.
Frontiers in Oncology (2021) Vol. 10
Open Access | Times Cited: 32
B-cell maturation antigen (BCMA) in multiple myeloma: the new frontier of targeted therapies
Larysa Sanchez, Alexandra Dardac, Deepu Madduri, et al.
Therapeutic Advances in Hematology (2021) Vol. 12
Open Access | Times Cited: 31
CART-Cell Therapy: Recent Advances and New Evidence in Multiple Myeloma
Massimo Martino, Filippo Antonio Canale, Caterina Alati, et al.
Cancers (2021) Vol. 13, Iss. 11, pp. 2639-2639
Open Access | Times Cited: 29
Belantamab Mafodotin: From Clinical Trials Data to Real-Life Experiences
Sonia Morè, Massimo Offidani, Laura Corvatta, et al.
Cancers (2023) Vol. 15, Iss. 11, pp. 2948-2948
Open Access | Times Cited: 12
Serum soluble BCMA can be used to monitor relapse of multiple myeloma patients after chimeric antigen receptor T-cell immunotherapy
Ying Shen, Jie Liu, Baiyan Wang, et al.
Current Research in Translational Medicine (2023) Vol. 71, Iss. 2, pp. 103378-103378
Closed Access | Times Cited: 11
Effect of prior lenalidomide or daratumumab exposure on hematopoietic stem cell collection and reconstitution in multiple myeloma
Hongpeng Duan, Qiuhui Jiang, Long Liu, et al.
Annals of Hematology (2024) Vol. 103, Iss. 10, pp. 3839-3853
Closed Access | Times Cited: 4
Single-Domain Antibodies as Antibody–Drug Conjugates: From Promise to Practice—A Systematic Review
Víctor Manuel Medina Pérez, Marta Baselga, Alberto J. Schuhmacher
Cancers (2024) Vol. 16, Iss. 15, pp. 2681-2681
Open Access | Times Cited: 4
Targeting GPRC5D for multiple myeloma therapy
Dian Zhou, Ying Wang, Chong Chen, et al.
Journal of Hematology & Oncology (2024) Vol. 17, Iss. 1
Open Access | Times Cited: 4

Scroll to top